Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Long Chang

Showing results (251-260 of 262) with videos related to

Pageof 27
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2011
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growthQian Sun, Xinxin Chen, Jianhui Ma, et al.
Urologia Internationalis|November 8, 2011
Melamine-related urinary stones in 195 infants and young children: clinical features within 2 years of follow-upJian Guo Wen, Qing Long Chang, An Feng Lou, et al.
Molecular & Cellular Proteomics : MCP|May 27, 2010
Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferationTzu-Hao Wang, Angel Chao, Chia-Lung Tsai, et al.
Gynecologic Oncology|May 24, 2025
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung-Yun Lee, Sathana Boonyapipat, Guangwen Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancerAna Oaknin, Bradley J Monk, Ignace Vergote, et al.
Journal of Medical Internet Research|June 16, 2026
Authoritative Textbook-Augmented Large Language Models for High-Altitude Public Health Medical Education in the Xizang Autonomous Region: Cross-Sectional Comparative Evaluation StudyKun He, Qiming Xiao, Wangyang Chen, et al.
Gynecologic Oncology|July 1, 2025
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancerLeslie Randall, Yang Xiang, Takashi Matsumoto, et al.
Lancet (London, England)|September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Lancet (London, England)|March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trialAna Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.
Pageof 27

Showing results (251-260 of 262) with videos related to

Sort By:
Pageof 27
Proceedings of the National Academy of Sciences of the United States of America|February 18, 2011
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growthQian Sun, Xinxin Chen, Jianhui Ma, et al.
Urologia Internationalis|November 8, 2011
Melamine-related urinary stones in 195 infants and young children: clinical features within 2 years of follow-upJian Guo Wen, Qing Long Chang, An Feng Lou, et al.
Molecular & Cellular Proteomics : MCP|May 27, 2010
Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferationTzu-Hao Wang, Angel Chao, Chia-Lung Tsai, et al.
Gynecologic Oncology|May 24, 2025
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancerJung-Yun Lee, Sathana Boonyapipat, Guangwen Yuan, et al.
European Journal of Cancer (Oxford, England : 1990)|August 3, 2022
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancerAna Oaknin, Bradley J Monk, Ignace Vergote, et al.
Journal of Medical Internet Research|June 16, 2026
Authoritative Textbook-Augmented Large Language Models for High-Altitude Public Health Medical Education in the Xizang Autonomous Region: Cross-Sectional Comparative Evaluation StudyKun He, Qiming Xiao, Wangyang Chen, et al.
Gynecologic Oncology|July 1, 2025
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancerLeslie Randall, Yang Xiang, Takashi Matsumoto, et al.
Lancet (London, England)|September 17, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
Lancet (London, England)|March 23, 2024
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trialDomenica Lorusso, Yang Xiang, Kosei Hasegawa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2025
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trialAna Oaknin, Bradley J Monk, Andreia Cristina de Melo, et al.
Pageof 27